Slide 1: Highlights FY25 & Outlook for FY26
For personal use only Highlights FY25 & Outlook for FY26 May 2025
Slide 2: For personal use only
TruScreen Sales Strategy TruScreen Highlights CY24 - CY25 For personal use only TruScreen Outlook: FY26 and Beyond
Slide 3: Who is TruScreen
Who is TruScreen Dual listed on the Australian (ASX) and New Zealand (NZX) stock exchanges, with a common ticker code of TRU. For personal use only TruScreen Group Ltd is a revenue generating Life Science company with FY25 annual sales of NZ$ 1.7m, down from $2.1m in FY24. This lower result was larg
Slide 4: TruScreen Price History (NZX)
TruScreen Price History (NZX) For personal use only 4
Slide 5: TruScreen Sales Strategy
For personal use only TruScreen Sales Strategy
Slide 6: TruScreen Sales Strategy
TruScreen Sales Strategy • TruScreen focuses on emerging economies such as China, India, Indonesia, Mexico, Uzbekistan, Vietnam and Zimbabwe. Unlike the developed western markets, these countries have no or minimal large-scale cervical cancer screening programs and infrastructure. For personal use o
Slide 7: Recurring Revenue Model
Recurring Revenue Model • TruScreen manufactures two devices – o one made in China for use in China, where locally manufactured products have For personal use only preferential market access o one made in Australia for other markets • For each patient screened with the TruScreen device a new disposa
Slide 8: Entry into Public Screening Programs
Entry into Public Screening Programs • TruScreen’s sales to date have been achieved largely through traditional sales of devices and Single Use Sensors to hospitals and clinics. In FY25 these traditional channels made up 99% of sales. For personal use only • Following the previous success of TruScre
Slide 9: TruScreen Regulatory Approvals
TruScreen Regulatory Approvals International Quality Recognized by International Approvals: Accreditation: World Health Organisation (WHO) • CE Mark, European Union For personal use only UNITAID • NMPA, China ISO 13485 • TGA, Australia Clinton Health Access Initiative ISO 60601- 1- 2 • MHRA, UK Daff
Slide 10: TruScreen's presence and global markets
TruScreen’s presence and global markets RUSSIA 48M, CENTRAL ASIA 13M For personal use only China UZBEKISTAN 477M MEXICO SAUDI 12M 46M 11M VIETNAM 36M ASEAN & INDONESIA 142M SOUTHERN INDIA & CENTRAL 468M Existing market AFRICA 134M Target market 10
Slide 11: TruScreen Highlights CY24 - CY25
For personal use only TruScreen Highlights CY24 - CY25
Slide 12: TruScreen and Dalton BioScience
TruScreen and Dalton BioScience MOU signed February 2025 between TruScreen Group Ltd and Hangzhou Dalton Bioscience For personal use only • TruScreen to distribute globally (excluding USA and Canada) via selected distributors DaltonBio HPV related IVD products including DNA tests and Self Sampling.
Slide 13: Key market China exceeded budget and is poised for expansion
Key market China, accounting for over 85% of global sales, exceeded budget and is poised for expansion in 6 key provinces • Key provinces for growth: TruScreen’s China distributor Beijing Siweixiangtai Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 - Guangxi, For personal u
Slide 14: China: private sector expansion and public health insurance
• Private Sector Expansion: SWXT targeting of the growing China private health sector including private clinic and Health Check Centre approvals in Jiangsu and Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine Hospital sectors. • Public Health Insurance: In addition to ha
Slide 15: TruScreen selected to screen 260,000 women in Ho Chi Minh City
TruScreen selected to screen 260,000 women in Ho Chi Minh City and adoption in Vietnam picks up pace • The formal agreement to conduct a 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City was signed in April 2025 For personal use only Following the signing of a Memorandum
Slide 16: TruScreen re-enters India with Renovate Biologicals
TruScreen re-enters India with appointment of Renovate Biologicals Pvt Ltd in April 2025 India holds one-sixth of the world's population and one woman dies from cervical cancer every eight minutes in the country. For personal use only The cervical cancer screening rate is only 2%, and India’s Nation
Slide 17: Indonesia product registration completed and distributor appointed
Indonesia product registration completed and distributor appointed, with commercial activity commenced in May 2025 • Distributor Appointed: Following the completion of product registration, INDONESIA For personal use only TruScreen appointed a new Indonesian medical products distributor PT 96 millio
Slide 18: Independent studies and WHO validation
TruScreen results and suitability in emerging markets continues to be validated by independent studies and the World Health Organization • October 2024 – UNITAID included TruScreen in its technology landscape report “Screening and For personal use only treatment of pre-cancerous lesions for secondar
Slide 19: WHO meeting and published studies
• November 2024 – following the UNITAID inclusion, TruScreen were invited to present at the World Health Organisation (WHO) key meeting to further the use of AI technologies for screening of cervical cancer in Edinburgh, and were the only opto-electric tissue differentiating medical device company i
Slide 20: TruScreen Outlook: FY26 and beyond
For personal use only TruScreen Outlook: FY26 and beyond
Slide 21: FY25 Sales (Actual) vs FY26 Sales (Projection)
FY25 Sales (Actual) FY26 Sales (Projection) NZ$ 1.71m NZ$ 2.8m +64% YOY increase with increased diversification of revenue For personal use only 21
Slide 22: TruScreen Expected Sales Increase FY26
TruScreen Expected Sales Increase FY26 NZ$ 2.8m Public Screening Expected sales Six key Program to Public > NZ$ 100k provinces resume; Screening to For personal use only Ho Chi Minh targeted; Expected sales commence; City Public Expected sales > NZ$ 300k Dalton Bio IVD Expected sales Screening incre
Slide 23: Growth Strategies
Growth Strategies Market expansion to continue with Strengthen vertical Asian market from China the key focus Indonesia through China, and capitalise on Indian distribution network For personal use only Focus on key growth provinces (Shandong, Target Govt and NGO funded Jiangsu,, Hunan, Zhejiang, Gu
Slide 24: Growth Strategies (cont.)
Growth Strategies (cont.) Focus on countries with limited or nil Expand product portfolio to include Dalton cervical screening capability Bio HPV related IVD products DNA tests, including HPV DNA tests and self sampling For personal use only Developing strategic partnerships for Reduce SUS and Devic
Slide 25: Contact us for more Information
Contact us for more Information For personal use only Martin Dillon Guy Robertson CEO Chief Financial Officer M - +61 449 115 065 M – +61 407 983 270 E – martindillon@truscreen.com E – guyrobertson@truscreen.com TruScreen TruScreen Suite 3.03 18 Orion Rd Suite 3.03 18 Orion Rd Lane Cove West NSW 206
Slide 26: References and Disclaimers
References *Women aged 15-64 years as detailed in the World Fact Book : https://www.cia.gov/the-world-factbook/ Disclaimers For personal use only This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information